HIV treatment failure: Testing for HIV resistance in clinical practice

Science

Volumn 280, Issue 5371, 1998, Pages 1871-1873

  Perrin, Luc ^a,b   Telenti, Amalio ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GAG PROTEIN; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR;

CLINICAL PRACTICE; COHORT ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT FAILURE; VIREMIA; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0032547101     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.280.5371.1871     Document Type: Short Survey

References (40)

1. J. Cohen, Science 279, 1133 (1998).
2. M. Egger et al., Br. Med. J. 315, 1194 (1997); Y. Mouton et al., AIDS 11, F101; F. Palella, N. Engl. J. Med. 338, 853 (1998); B. Hirschel and P. Francioli, ibid., p. 906.
3. M. Egger et al., Br. Med. J. 315, 1194 (1997); Y. Mouton et al., AIDS 11, F101; F. Palella, N. Engl. J. Med. 338, 853 (1998); B. Hirschel and P. Francioli, ibid., p. 906.
4. M. Egger et al., Br. Med. J. 315, 1194 (1997); Y. Mouton et al., AIDS 11, F101; F. Palella, N. Engl. J. Med. 338, 853 (1998); B. Hirschel and P. Francioli, ibid., p. 906.
5. M. Egger et al., Br. Med. J. 315, 1194 (1997); Y. Mouton et al., AIDS 11, F101; F. Palella, N. Engl. J. Med. 338, 853 (1998); B. Hirschel and P. Francioli, ibid., p. 906.
6. J. K. Wong et al., Science 278, 1291 (1997); D. Finzi et al., ibid, p. 1295; T. W. Chun et al., Proc. Natl. Acad. Sci. U.S.A. 24, 13193 (1997).
7. J. K. Wong et al., Science 278, 1291 (1997); D. Finzi et al., ibid, p. 1295; T. W. Chun et al., Proc. Natl. Acad. Sci. U.S.A. 24, 13193 (1997).
8. J. K. Wong et al., Science 278, 1291 (1997); D. Finzi et al., ibid, p. 1295; T. W. Chun et al., Proc. Natl. Acad. Sci. U.S.A. 24, 13193 (1997).
9. C. C. J. Carpenter et al., J. Am. Med. Assoc. 277, 1962 (1997).
10. Lorenzi et al., AIDS 11, F 95 (1997).
11. B. Autran et al., Science 277, 112 (1997).
12. D. Kaufmann, G. Pantaleo, P. Sudre, A. Telenti, Lancet 351, 723 (1998); S. Deeks, abstract 419 presented at the Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, 1998 (Foundation for Retrovirology and Human Health, Alexandria, VA).
13. D. Kaufmann, G. Pantaleo, P. Sudre, A. Telenti, Lancet 351, 723 (1998); S. Deeks, abstract 419 presented at the Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, 1998 (Foundation for Retrovirology and Human Health, Alexandria, VA).
14. D. D. Ho et al., Nature 373, 123 (1995); N. Sachsenberg et al., J. Exp. Med. 187, 1295 (1998), M. Roederer, Nature Med. 4, 145 (1998).
15. D. D. Ho et al., Nature 373, 123 (1995); N. Sachsenberg et al., J. Exp. Med. 187, 1295 (1998), M. Roederer, Nature Med. 4, 145 (1998).
16. D. D. Ho et al., Nature 373, 123 (1995); N. Sachsenberg et al., J. Exp. Med. 187, 1295 (1998), M. Roederer, Nature Med. 4, 145 (1998).
17. G. Fatkenheuer et al., AIDS 11, F113 (1997).
18. Transmission of isolates carrying azidothymidine resistance mutations occurs in 5 to 10% of episodes of primary infection and of perinatal contamination. Transmission of nevirapine-resistant clones has also been reported. [Imrie et al., J. Infect. Dis. 175, 1502 (1997); Qiugg et al., AIDS 11, 835 (1997); S. Yerly et al., Schweiz. Med. Wochensch. 126, 1845 (1996)]. Transmission of multidrug-resistant HIV carrying mutations to protease inhibitors has recently been observed by S. Yerly et al. (personal communication).
19. Transmission of isolates carrying azidothymidine resistance mutations occurs in 5 to 10% of episodes of primary infection and of perinatal contamination. Transmission of nevirapine-resistant clones has also been reported. [Imrie et al., J. Infect. Dis. 175, 1502 (1997); Qiugg et al., AIDS 11, 835 (1997); S. Yerly et al., Schweiz. Med. Wochensch. 126, 1845 (1996)]. Transmission of multidrug-resistant HIV carrying mutations to protease inhibitors has recently been observed by S. Yerly et al. (personal communication).
20. Transmission of isolates carrying azidothymidine resistance mutations occurs in 5 to 10% of episodes of primary infection and of perinatal contamination. Transmission of nevirapine-resistant clones has also been reported. [Imrie et al., J. Infect. Dis. 175, 1502 (1997); Qiugg et al., AIDS 11, 835 (1997); S. Yerly et al., Schweiz. Med. Wochensch. 126, 1845 (1996)]. Transmission of multidrug-resistant HIV carrying mutations to protease inhibitors has recently been observed by S. Yerly et al. (personal communication).
21. Transmission of isolates carrying azidothymidine resistance mutations occurs in 5 to 10% of episodes of primary infection and of perinatal contamination. Transmission of nevirapine-resistant clones has also been reported. [Imrie et al., J. Infect. Dis. 175, 1502 (1997); Qiugg et al., AIDS 11, 835 (1997); S. Yerly et al., Schweiz. Med. Wochensch. 126, 1845 (1996)]. Transmission of multidrug-resistant HIV carrying mutations to protease inhibitors has recently been observed by S. Yerly et al. (personal communication).
22. N. A. Roberts, J. C. Craig, J. Sheldon, AIDS 12, 453 (1998); D. V. Havlir, D. D. Richmann, J. Virol. 70, 7894 (1996).
23. N. A. Roberts, J. C. Craig, J. Sheldon, AIDS 12, 453 (1998); D. V. Havlir, D. D. Richmann, J. Virol. 70, 7894 (1996).
24. Y.-M. Zhang et al., J. Virol. 71, 6662 (1997); L. Stuyver et al., Antimicrob. Agents Chemother. 41, 284 (1997); M. J. Kozal et al., Nature Med. 2, 753 (1996).
25. Y.-M. Zhang et al., J. Virol. 71, 6662 (1997); L. Stuyver et al., Antimicrob. Agents Chemother. 41, 284 (1997); M. J. Kozal et al., Nature Med. 2, 753 (1996).
26. Y.-M. Zhang et al., J. Virol. 71, 6662 (1997); L. Stuyver et al., Antimicrob. Agents Chemother. 41, 284 (1997); M. J. Kozal et al., Nature Med. 2, 753 (1996).
27. R. F. Schinazi, B. A. Larder, J. W. Mellors, Int. Antiviral News 5, 129 (1997).
28. R. W. Shafer et al., J. Infect. Dis. 169, 722 (1994); M. Nijhuis et al., ibid. 176, 398 (1997); M. A. Winters et al., Antimicrob. Agents Chemother. 41, 757 (1997).
29. R. W. Shafer et al., J. Infect. Dis. 169, 722 (1994); M. Nijhuis et al., ibid. 176, 398 (1997); M. A. Winters et al., Antimicrob. Agents Chemother. 41, 757 (1997).
30. R. W. Shafer et al., J. Infect. Dis. 169, 722 (1994); M. Nijhuis et al., ibid. 176, 398 (1997); M. A. Winters et al., Antimicrob. Agents Chemother. 41, 757 (1997).
31. R. Jellinger, R. Shafer, T. Merigan, J. Infect. Dis. 175, 561 (1996); K. Hertogs et al., Antimicrob. Agents Chemother. 42, 269 (1998).
32. R. Jellinger, R. Shafer, T. Merigan, J. Infect. Dis. 175, 561 (1996); K. Hertogs et al., Antimicrob. Agents Chemother. 42, 269 (1998).
33. A. Gervaix et al., Proc. Natl. Acad. Sci. U.S.A. 94, 4653 (1997); A. Gervaix, personal communication.
34. A. Gervaix et al., Proc. Natl. Acad. Sci. U.S.A. 94, 4653 (1997); A. Gervaix, personal communication.
35. Although resistance mutations to one of the nucleoside analogs in HAART may not preclude long-term viral suppression, it does predict early rebound if treatment is simplified [J. K. Wong et al., Science 278, 1291 (1997); R. Raffi et al., abstract LB15 presented at the Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, 1998 (Foundation for Retrovirology and Human Health, Alexandria, VA); D. V. Havlir et al., ibid, abstract LB16].
36. Although resistance mutations to one of the nucleoside analogs in HAART may not preclude long-term viral suppression, it does predict early rebound if treatment is simplified [J. K. Wong et al., Science 278, 1291 (1997); R. Raffi et al., abstract LB15 presented at the Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, 1998 (Foundation for Retrovirology and Human Health, Alexandria, VA); D. V. Havlir et al., ibid, abstract LB16].
37. Although resistance mutations to one of the nucleoside analogs in HAART may not preclude long-term viral suppression, it does predict early rebound if treatment is simplified [J. K. Wong et al., Science 278, 1291 (1997); R. Raffi et al., abstract LB15 presented at the Fifth Conference on Retrovirus and Opportunistic Infections, Chicago, 1998 (Foundation for Retrovirology and Human Health, Alexandria, VA); D. V. Havlir et al., ibid, abstract LB16].
38. Once virological failure takes place, resistance testing confirms the presence of mutant viruses. Rarely, if no mutation is identified, it may suggest the possibility of retaining one of the drugs of the combination or the existence of problems in adherence to the treatment [D. Mayers et al., abstract presented at the International Workshop on HIV Drug Resistance, Treatment Strategies, and Eradication, St. Petersburg, FL, 1997].
39. L. Perrin and A. Telenti, unpublished data.
40. We thank D. Kaufmann and S. Yerly for invaluable help. Supported by the Swiss National Science Foundation and the Swiss Federal Office for Public Health.